Identifying Blood and Cognitive Markers for Antidepressant Response in Depression
Author Information
Author(s): André Tadić, Stefanie Wagner, Stanislav Gorbulev, Norbert Dahmen, Christoph Hiemke, Dieter F. Braus, Klaus Lieb
Primary Institution: University Medical Centre, Mainz, Germany
Hypothesis
Can peripheral blood and neuropsychological markers predict the onset of action of antidepressant drugs in patients with Major Depressive Disorder?
Conclusion
The study aims to identify biomarkers that could help predict treatment response in patients with Major Depressive Disorder, potentially improving remission rates.
Supporting Evidence
- Many studies suggest that early improvement in depressive symptoms can predict final treatment outcomes.
- Identifying biomarkers could lead to more personalized and effective antidepressant treatments.
- Previous research indicates that true drug response can be observed within the first 10-14 days of treatment.
Takeaway
This study is trying to find clues in blood and brain function that can tell us how well antidepressants will work for people with depression.
Methodology
The study involves a multi-centre, randomized controlled trial with repetitive measurements of blood and cognitive parameters over eight weeks.
Potential Biases
Potential biases may arise from the selection of participants and the matching process between patients and healthy controls.
Limitations
The study may face challenges in identifying specific biomarkers due to the complexity of depression and individual variability in treatment response.
Participant Demographics
The study includes adult and elderly patients with Major Depressive Disorder, aged 18-65, and healthy controls matched by age, sex, and intelligence.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website